MetaVia Announces Interim Data From Part 3B Of Its Phase 1 Clinical Trial Of DA-1726 Targeting Both GLP-1 And Glucagon Receptors; Results Demonstrate 68% Placebo-Adjusted Reduction In Liver Fat And 13.5% Placebo-Adjusted Body Weight Reduction Following 16 Weeks Of Once-Weekly DA-1726 Treatment In Otherwise Healthy Adults With Obesity; Plans Phase 2 For H2 2027
At Day 109, 10 of 12 DA-1726-treated participants (83%) in the MRI substudy achieved a relative liver fat reduction of at least 30%, compared with none on placebo. All DA-1726-treated participants with baseline liver
MetaVia's experimental weight loss drug showed strong results in early testing. The company plans to move forward with larger studies next year.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.